title: Meaningful use and clinical utility of preemptive pharmacogenetic testing: (re)view from a CYP2D6 poor metabolizer.
abstract: The value of pharmacogenetic information at an individual level seems self-evident; demonstrating the value to the individual across a population appears to be much more difficult to demonstrate. Future studies should avoid single gene-drug pairs and a limited number of population-specific alleles that are insufficient to capture all relevant genetic variation within diverse populations, such as CYP2C9*2 and *3. Robust associations between cytochrome P450 (CYP) genotypes and treatment response require knowledge of drug exposure.
authors: Marion Merrell Dow/Missouri Endowed Chair in Pediatric Clinical Pharmacology, Director, Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Professor of Pediatrics and Pharmacology, Schools of Medicine and Pharmacy, University of Missouri-Kansas City, Missouri, USA.
authors: J Steven
authors: JS
authors: Leeder
mesh_terms: D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005820:Genetic Testing / Q000592:standards*; D006801:Humans; D010597:Pharmacogenetics / Q000592:standards*
chemical_list: D003577:Cytochrome P-450 Enzyme System